| 06.05 14:10 | dpa-AFX: Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation |
| 06.05 13:56 | dpa-AFX: *BMY :OPDIVO + YERVOY GRANTED EMA VALIDATION FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER |
| 30.04 19:48 | dpa-AFX: Biotech Stocks Facing FDA Decision In May 2024 |
| 29.04 12:26 | dpa-AFX: Repertoire Immune Medicines In Strategic Partnership With Bristol Myers Squibb |
| 29.04 12:02 | dpa-AFX: *REPERTOIRE® IMMUNE MEDICINES, BRISTOL MYERS SQUIBB ENTER STRATEGIC COLLABORATION TO DEVELOP TOLERIZING VACCINES |
| 26.04 15:38 | dpa-AFX: Bristol Myers: CHMP Recommends Approval Of Opdivo In Combination With Cisplatin And Gemcitabine |
| 26.04 15:09 | dpa-AFX: *CHMP BACKS BRISTOL-MYERS' OPDIVO COMBO FOR UROTHELIAL CARCINOMA |
| 26.04 06:00 | dpa-AFX: *RPT/JEFFERIES CUTS BRISTOL-MYERS SQUIBB PRICE TARGET TO 54 (56) USD - 'HOLD' |
| 26.04 06:00 | dpa-AFX: *WDH/JEFFERIES SENKT ZIEL FÜR BRISTOL-MYERS SQUIBB AUF 54 (56) USD - 'HOLD' |
| 25.04 18:29 | dpa-AFX: *JEFFERIES CUTS BRISTOL-MYERS SQUIBB PRICE TARGET TO 54 (56) USD - 'HOLD' |
| 25.04 18:29 | dpa-AFX: *JEFFERIES SENKT ZIEL FÜR BRISTOL-MYERS SQUIBB AUF 54 (56) USD - 'HOLD' |
| 25.04 13:41 | dpa-AFX: Bristol Myers Squibb Posts Loss In Q1; Updates 2024 Non-GAAP EPS Guidance |
| 25.04 13:19 | dpa-AFX: Bristol-Myers Squibb Co. Q1 Earnings Summary |
| 25.04 13:03 | dpa-AFX: Bristol-Myers Squibb Q1 24 Earnings Conference Call At 8:00 AM ET |
| 25.04 13:02 | dpa-AFX: *BRISTOL MYERS SQUIBB Q1 LOSS PER SHARE $5.89; NON-GAAP LOSS PER SHARE $4.40 |
| 05.04 16:04 | dpa-AFX: Bristol Myers, 2seventy Bio Get FDA Nod For Abecma For Relapsed Multiple Myeloma Patients |
| 05.04 15:46 | dpa-AFX: *FDA APPROVES BRISTOL MYERS AND 2SEVENTY BIO'S ABECMA FOR TRIPLE-CLASS EXPOSED R/R MULTIPLE MYELOMA |
| 01.04 13:56 | dpa-AFX: Zai Lab: Bristol Myers' KRYSTAL-12 Confirmatory Trial With Adagrasib Meets Meets Primary Endpoint |
| 01.04 13:40 | dpa-AFX: *ZAI LAB : BRISTOL MYERS' PIVOTAL TRIAL CONFIRMS POSITIVE RESULTS FOR ITS KRAZATI IN LUNG CANCER |
| 19.03 13:08 | dpa-AFX: Perspective Therapeutics Inks Clinical Trial Collaboration Agreement With Bristol Myers |
|
|
